Singapore markets closed

REGN Aug 2024 750.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
11.000.00 (0.00%)
At close: 10:13AM EDT
Full screen
Previous close11.00
Open3.90
Bid0.00
Ask4.80
Strike750.00
Expiry date2024-08-16
Day's range3.90 - 11.00
Contract rangeN/A
Volume1
Open interest32
  • Benzinga

    Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data

    On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. Specifically, the approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) or on a combination of LABA and LAMA if ICS is not appropriate. Sanofi SA (NASDAQ

  • Zacks

    Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD

    Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.

  • Reuters

    EU approves Sanofi's Dupixent for 'smoker's lungs'

    The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs, Sanofi said in a statement, following a recommendation by the European Medicines Agency (EMA) at the end of May. The debilitating disease is also known as 'smoker's lungs' because in western countries it primarily affects cigarette smokers.